Advertisement
Advertisement
U.S. markets close in 4 hours 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

CorMedix Inc. (CRMD)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
2.8900-0.1200 (-3.99%)
As of 10:45AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.0100
Open2.9900
Bid2.8800 x 800
Ask2.9100 x 800
Day's Range2.8700 - 3.0900
52 Week Range2.6500 - 8.0300
Volume17,441
Avg. Volume444,365
Market Cap119.092M
Beta (5Y Monthly)2.32
PE Ratio (TTM)N/A
EPS (TTM)-0.7350
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CRMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CorMedix Inc.
    Daily – Vickers Top Buyers & Sellers for 09/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference

    BERKELEY HEIGHTS, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will be presenting a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in New York on September 12 – 14, 2022. H.C. Wainwright Annual Global Investment Conference Date: Monday,

  • GlobeNewswire

    CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update

    Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the second quarter and six months ended June 30, 2022 and provided an update on recent business events. Recent Corporate Highlights: CorMedix announc

  • Benzinga

    CorMedix Slapped With Second FDA Rejection For DefenCath

    CorMedix Inc (NASDAQ: CRMD) received a second Complete Response Letter (CRL) from the FDA for DefenCath, developed as a catheter lock solution to reduce catheter-related bloodstream infections in patients with renal failure receiving chronic hemodialysis via a central venous catheter. The letter states that DefenCath cannot be approved until deficiencies recently conveyed to the contract manufacturing organization and the supplier of the active pharmaceutical ingredient heparin during inspection

Advertisement
Advertisement